Atorvastatin added to interferon β for relapsing multiple sclerosis: a randomized controlled trial.

J Neurol · 2012 · PMC3484273 · PMID 22569835

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Patients in the atorvastatin/IFNB-1b group were significantly younger, showed a trend towards higher disease activity at baseline, and had significantly larger volumes of Gd-enhancing lesions on T1-weighted images.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.